Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for critically and chronically ill patients. Its portfolio includes intravenous drugs, clinical nutrition, medical technologies, and biopharmaceuticals designed to improve patient care and treatment efficiencies worldwide.
Subscribe to see Fresenius Kabi’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Fresenius Kabi is a healthcare company headquartered in Sweden. Xcout tracks 7 named people at Fresenius Kabi, including Pierluigi Antonelli (President and CEO of Fresenius Kabi). Xcout recorded 4 job postings from Fresenius Kabi in the last 90 days.
1 more named person on record for Fresenius Kabi, with roles, board committees and tenure — see the full roster →
Xcout recorded 4 job postings from Fresenius Kabi in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Fresenius Kabi's hiring signals →
A few of Fresenius Kabi's closest competitors — see the full list of competitors and alternatives →
Fresenius Group is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany, comprising operating companies such as Fresenius Kabi.
Uniphar Group is a diversified healthcare services company providing medical device distribution, pharmaceutical supply chain, and retail services.
B. Braun is a leading global medical technology company providing healthcare products, solutions, and services worldwide.
CareFusion Corporation was a medical company specializing in two areas: reducing medication errors and prevention of health care-associated infections.
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artificial kidney dialysis, as well as various medical instruments and apparatus. Additionally, the company participates in real estate leasing. Established in 1937, Fuso Pharmaceutical's corporate headquarters are situated in Osaka, Japan.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.